[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100503756":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":20,"studyPopulation":13,"armGroups":13,"interventions":21,"overallOfficials":26,"centralContacts":31,"locations":41,"responsibleParty":57,"collaborators":13,"id":59,"slug":13,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":13,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":13,"enrollmentInfo":67,"targetDuration":13,"studyType":70,"phases":71,"briefSummary":72,"conditions":73,"keywords":13,"overallStatus":44,"whyStopped":13,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Gruppo Italiano Malattie EMatologiche dell'Adulto","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Identification of MECOM\u002FEVI1 regulators or downstream effectors potentially druggable","To assess the number of regulators or effectors of MECOM\u002FEVI1","At baseline",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"NA","SINGLE_GROUP","BASIC_SCIENCE",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE","This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements. To this end, BM samples and formalin fixed\u002Fparaffin-embedded BM biopsies will be collected at enrolment, before and after treatment, at relapse.",[22],{"type":23,"name":24,"description":25,"armGroupLabels":13,"otherNames":13},"BIOLOGICAL","Biological characterization of AML with MECOM or atypical 3q26 rearrangements","Peripheral blood and bone marrow withdrawal",[27],{"name":28,"affiliation":29,"role":30},"Giovanni Roti","Department of Medicine and Surgery, University of Parma, Parma","PRINCIPAL_INVESTIGATOR",[32,37],{"name":33,"role":34,"phone":35,"phoneExt":13,"email":36},"Paola Fazi","CONTACT","0670390528","p.fazi@gimema.it",{"name":38,"role":34,"phone":39,"phoneExt":13,"email":40},"Enrico Crea","0670390514","e.crea@gimema.it",[42],{"facility":43,"status":44,"city":45,"state":13,"zip":13,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Ematologia","RECRUITING","Piacenza","Italy","IT",{"type":49,"coordinates":50},"Point",[51,52],9.69342,45.05242,{"lat":52,"lon":51},[55],{"name":56,"role":34,"phone":13,"phoneExt":13,"email":13},"Vallisa",{"type":58,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100503756",false,"NCT05839392","Novel Approaches to Target MECOM\u002FEVI1 in AML","Novel Approaches to Target MECOM\u002FEVI1 in Acute Myeloid Leukemia","Inclusion Criteria:\n\n* AML with MECOM or atypical 3q26 rearrangements.\n* Age ≥18.\n* Signed written informed consent according to ICH\u002FEU\u002FGCP and national local laws.\n\nExclusion Criteria:\n\n* None","ALL","18 Years",{"count":68,"type":69},24,"ESTIMATED","INTERVENTIONAL",[15],"This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements.",[74],"AML, Adult","2023-12-22",{"date":77,"type":78},"2023-12-29","ACTUAL",{"date":80,"type":78},"2023-12-13",{"date":82,"type":69},"2026-12",{"name":5,"class":6},1]